Uptick In 4Q 2013 M&A Deal-Making Likely To Continue Into 2014, PwC Report Predicts
This article was originally published in The Pink Sheet Daily
Earn-outs and other deal tools help bridge value gaps and share risk, enabling more deals to be finalized, report says. However, pharma is seeing increased M&A competition from biotechs looking to diversify and increase scale.
You may also be interested in...
Amgen’s $125 Per Share Offer For Onyx Reflects Kyprolis Uncertainty
Amgen will acquire the cancer company Onyx for $125 per share, or $10.4 billion. That's higher than the $120 per share Amgen originally offered, but less than some investors and analysts thought obtainable.
Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE
Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.
The Street Assesses AbbVie
With a market cap of a Bristol-Myers or Eli Lilly, AbbVie is worth more in early trading than the remaining Abbott. If it can keep growing Humira sales while making its pipeline pay-off, it will be the poster child for slimmed-down and refashioned pharma.